We Create Your Equity Story
Nice to Meet You
We are a trusted partner for Pharma and Biotech executives as well as investment professionals for more than 20 years.
Our combination of scientific excellence with business acumen delivers assessments and valuations that senior management uses for investment decisions, R&D portfolio optimization, and negotiation of partnering deals. In particular, we support our clients in maximizing value from licensing deals, M&A transactions, IPOs and private funding rounds.
LATEST NEWS
The post-pandemic BioPharma industry in 2021, 4 new KPIsThe BioPharma industry is going through a transition period. The traditional commercial launch model is no longer sustainable, and the pandemic made it redundant. As companies continue to move toward a new model, they must answer a key question...
READ MORE
Benefit from our support and avoid up to 25% of Phase II and Phase III failures!
Who We Are
Who Are You?
What We Offer
Our Clients
We are working with Biotech, Medtech, Pharma and Animal Health companies, as well as investors. In our 20-years-old company history, we advised clients on over 500 mandates. Take a look at our client list!
Our Publications
We demonstrate our thought leadership by numerous scientific and business publications. We are experts in both the scientific, and the business world. Check out our publication list!
Downloads
Please feel free to download the newest articles on BSV’s assessments and services. We inform you on our state-of-the-art services and keep you updated with newly introduced indices. Read our publications here.
Rick Jackson, Chairman and CEO Jackson Healthcare
“Both, breadth and depth of Bioscience Valuation’s economic assessments as well as the company’s excellent knowledge of healthcare markets are invaluable assets for me in order to reach my goals.”
Prof. Dr. Thomas Danne, Director, and Dr. Bärbel Aschemeier, Clinical Research, AUF DER BULT Hospital for Children and Adolescents
“With the dedicated support, and particularly the experienced, constructive work of Bioscience Valuation, we accomplished meaningful results that provide important new knowledge enabling our next steps in diabetes research. We sincerely thank the entire Bioscience Valuation team for their valuable and straightforward collaboration in the past year, and look forward to the next opportunity of working with them again.”
Dr. Adi Hoess, CEO Affimed
“Bioscience Valuation’s services help me to communicate the value of our business to various stakeholders, including investors.”
Dr. Folker Ruchatz, SVP Contract Manufacturing Business, Boehringer Ingelheim Biopharmaceuticals GmbH
“I am impressed with Bioscience Valuation’s professional approach that enables us to plan future revenues and capacity utilization much better now.”
Dr. Axel Wiest, COO R&D, Merck-Serono
“I like the insights gained from Bioscience Valuation’s thorough assessments that allow me to support my decisions with well-founded, rational arguments.”
Prof. Dr. Klaus Nickisch, CSO Evestra Inc., formerly Head of Project Management at Bayer Schering Pharma AG
“Bioscience Valuation’s unique approach to portfolio management clearly enhanced the value of our R&D pipeline.”
Dr. Philipp R. Hoffmann, Senior Director Business Development & Licensing Europe, Daiichi Sankyo
“Bioscience Valuation’s comprehensive assessments of in-licensing candidates provide us with a thorough understanding of the opportunity, both from a scientific and business perspective.”
Dr. Ulrich Jahnel, Senior VPHead of External Innovation, Grünenthal
“We greatly enjoy working with Bioscience Valuation; the company’s ‘Corporate Partnership Program’ is a great offering that provides in-depth analyses of significant economic value at fair cost.”
Peter Llewellyn-Davies, CFO/CBOMedigene AG
“Through its ‘Corporate Partnership Program’, Bioscience Valuation has provided exceptional support in the transformation of our business model. BSV’s evidence-based assessments proved invaluable for our strategic decision making as well as for preparing our corporate transactions.”
